Generated through a proprietary treatment of dividing cells, division arrested cells do not require lengthy and laborious cell culture procedures to prepare live cells for screening assays
Invitrogen launches the first suite of 60 division arrested cell lines for conveniently and cost-effectively screening a broad range of therapeutic targets.
Division arrested cells may be plated and assayed within 24 hours of thawing, and cell numbers increase only marginally after plating, thereby removing the variability caused by cell division during the course of an assay and providing more consistent results.
Division arrested cells show agonist-induced responses virtually indistinguishable from that of dividing cells, and exhibit no toxicity or apparent changes in signal transduction, ensuring researchers obtain the correct pharmacological profile.
The collection includes a broad range of cell lines developed for functional cell-based assays of G-protein coupled receptors, nuclear hormone receptors and hERG.
The cell lines are available in two configurations: 1x 384-well plate assay kits (including detection reagents) for small scale screening or evaluation purposes, and 10x384-well-plate kits for small to large scale screening.
Invitrogen acquired division arrest technology last year through the acquisition of Sentigen.
As part of the Sentigen transaction, Invitrogen owns the patent family which includes US Patent 7,045,281 and Australian Patent 2003270073.
Additional patent applications are currently pending in this family in the United States and a number of other countries.
